Buyer assessment
What this record supports
Biochimpharm's modernized bacteriophage facility has historical EU institutional corroboration. Georgian GMP certification was reported in September 2023, and the company continues to describe GMP-standard production in 2026; neither establishes the scope or expiry of a current certificate. The historical claim of up to 30 million vials a year is not audited current output. Before evaluating regulated products or development work, obtain the current manufacturing authorization and certificate for the exact facility, product and destination market.
Source mix: 3 reviewed sources are outside the company’s own web domain. This adds corroboration, but it does not make every operating claim independently verified.
This profile supports initial discovery and diligence planning. It is not evidence that the company has available capacity, meets a buyer’s compliance standard or has been commercially approved.
Public offering
Products and services shown publicly
Facility geography
Known locations and operating sites
Public company address; facility investment independently corroborated
Public company address
Company address · Tbilisi
Operating evidence
Documented capabilities and claims
Capabilities
Research, development, commercialization and manufacture of bacteriophage products
Company StatedEvidence checked Sep 17, 2026Facilities
Modernized manufacturing facility opened in 2022 following a EUR 6 million project
Institutionally CorroboratedEvidence checked Sep 17, 2026Historical company material states capacity of up to 30 million vials per year; current output and available capacity are unknown.
Historical Company Stated Capacity Not Independently VerifiedEvidence checked Nov 2, 2026Certifications
Facility described as converted and equipped in line with EU GMP guidelines
Not A Current CertificateEvidence checked Sep 17, 2026Georgian national GMP certification was reported in September 2023; the company continues to describe GMP-standard production in 2026. A current certificate number, scope and expiry have not been verified.
Historical Media Report And Current Company Statement Not Current CertificateEvidence checked Nov 2, 2026Qualification gaps
Questions to ask next
These are the highest-priority questions raised by the missing public evidence.
- Obtain current certificate or audit documents and verify the legal entity, facility, scope, issuer and expiry date.
- Request current line-level capacity, utilization and actual output for the relevant product.
- Request recent export markets and shipment evidence for the products under consideration.
- Confirm whether private-label or contract work is accepted, including development terms and ownership of tooling or artwork.
- Confirm MOQ by style, SKU and color, including sample and repeat-order minimums.
See every unverified field
- Current GMP Certificate
- Certificate Scope And Expiry
- Current Output And Available Capacity
- Export Markets
- Contract Manufacturing
- MOQ
- Lead Time
- Employee Count
Evidence log
Sources
- Biochimpharm aboutTier 1 · Accessed Sep 17, 2026
- Biochimpharm contactTier 1 · Accessed Sep 17, 2026
- EU Delegation to Georgia facility announcementTier 1 · Accessed Sep 17, 2026 · Recheck on 2 November 2026 returned HTTP 429. Retained as historical institutional evidence; a rate-limit response does not establish a permanently broken link.
- Biochimpharm company history stating a 1999 foundingTier 1 · Accessed Oct 5, 2026 · KA
- Biochimpharm dated news: GMP statements and historical production scaleTier 1 · Accessed Nov 2, 2026 · KA
- BM.GE report of Biochimpharm receiving Georgian GMP certificationTier 2 · Accessed Nov 2, 2026 · KA
- National Agency of Public Registry search result for identification code 211391554Tier 1 · Accessed Oct 5, 2026 · KA